KANCERA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.704 SEK | -4.80% |
|
+1.43% | -62.51% |
| 08/05 | Kancera AB Announces Executive Changes | CI |
| 03/05 | Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KANCERA AB | Bio Therapeutic Drugs | -4.80% | +1.43% | -62.51% | -41.54% | -84.37% | 20.22M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- KAN Stock
- Charts Kancera AB
- Comparison Chart
